Close Menu

CHICAGO – At the American Society of Clinical Oncology annual meeting this week, researchers presented new data on treatments for non-small cell lung cancer patients with ALK rearrangements and MET alterations in their tumors.

The data suggest that the precision oncology drug market in NSCLC will get even more crowded in the coming months and years, and patient populations will be further dissected according to molecular tumor characteristics.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.